Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
about
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016Liver resection and transplantation in hepatocellular carcinomaManagement strategies for hepatocellular carcinoma: old certainties and new realities.Acute heart failure caused by a giant hepatocellular metastatic tumor of the right atrium.Establishment of a human hepatoma multidrug resistant cell line in vitroRapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceAdjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trialPost-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomyThe Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma.Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case reportRMP predicts survival and adjuvant TACE response in hepatocellular carcinoma.Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.Future perspectives for hepatocellular carcinoma.Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study.The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.The Histologic Cut-off Point for Adjacent and Remote Non-neoplastic Liver Parenchyma of Hepatocellular Carcinoma in Chronic Hepatitis B Patients.Hepatocellular carcinoma: therapy and prevention.A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Current status of multimodal & combination therapy for hepatocellular carcinoma.Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinomaFibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes.Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis.Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma.TACE versus TAE as therapy for hepatocellular carcinoma.Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.Outcomes of hepatic resection for huge hepatocellular carcinoma (≥ 10 cm in diameter).HCV-related liver cancer in people with haemophilia.Hepatocellular carcinoma and vitamin D: a review.HCC: current surgical treatment concepts.The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011.Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma (≥ 5 cm in diameter).Malignant disease in the haemophilic population: moving towards a management consensus?Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.Postoperative therapy options for hepatocellular carcinoma.
P2860
Q26752478-51808439-8C6E-4D92-BC1E-1E5F966096C4Q26823395-1A5563CC-4AE0-4F70-A6D5-679A10BF93C2Q30252143-13CBF8BF-B758-4C4C-9FD8-CD59C34C803AQ33160380-9F21A37E-94EC-4CF9-836F-E9031E80EF90Q33574625-329B88FA-5AAB-4827-AF43-6D9ABA87A1CCQ33990018-71356E2F-774C-4C73-8C82-E4463F199EC6Q34093919-4E205A1F-3223-4A0D-80C4-A406D4BA6218Q34612069-A57F6599-9CFF-4248-A930-C80E522120D4Q34827366-77558D23-EDA4-480F-B3E4-55CDF7D3C5B5Q35012084-C4C5CAF8-59B8-49A0-AAA2-193B5AD5BC50Q35241955-788D419D-0CC2-47A4-BFB7-B98518DB69F2Q35478306-22CA07F7-43EC-4D28-8B35-A447A1E6363BQ35550266-E6DB7377-7442-4D9F-B7FE-AAE8DED99FD9Q35894880-7A382A20-5E78-4C7A-AD12-3B0815B42662Q36063224-ACC03E05-AA25-4BD5-B216-FB15F1D0591AQ36065568-D9375829-0193-4C41-A7B1-ABC0125AF80AQ36090448-FA275E65-107D-478F-ADBA-EFD02C3A6103Q36343700-EA3A4C7D-D8CF-4C60-9C22-A96D2C9413E6Q36377949-94FA2A89-6107-4F83-8626-59D755AA6266Q36432130-2F744CE4-4445-4BB5-8769-95BA57D956B5Q36436294-FEA7BC1C-EFE6-4CAD-BA5C-B9F114AC33B1Q36476765-0E4E834D-5DA6-43B8-ABEF-5FAFBB04178EQ36492831-E5F215A5-FCE7-499B-B761-639D392F052DQ36497118-C90036D8-882C-4A11-8666-2B9DDFC48792Q36580721-D016B760-9860-46A4-9DC9-B6D4D16B768DQ36899877-D40C083D-8B80-4C96-BD14-D6BE2FEB4D10Q36934253-56097591-A8C2-49B6-819D-A923F5D4E968Q36945072-032FB384-1F47-43CF-A99B-FA24BF0ED5CCQ37300023-D5AA49C3-3F1F-423D-8833-F0000F7034CBQ37701106-E451EA89-65F0-4785-B7C4-AE9CF7DCF66BQ37861629-BFA592EB-0D2D-488B-9425-E03A2E4B84BFQ37886275-17353106-CD3C-4504-85CA-14FD2874013FQ37924314-B4C4EF3D-0702-464C-8091-627458056F60Q37980015-C47D592B-FD28-406B-A459-C14C58DF6EB5Q37995237-C3FE7DD4-E4B6-47AD-9982-9F3B20F75191Q37996367-EE826E07-7A3D-48CE-A3EE-B702AC701A4EQ38013149-C6BE52CF-3145-48D2-BED7-D4DF2B28786BQ38045000-0C2D38DF-F4A4-4431-A40A-1811C4981F1AQ38073121-A13C1F5D-0F24-4352-BC5D-C316EBB98A8AQ38203306-A586A316-3049-4237-B2E6-446701843A92
P2860
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@ast
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@en
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@nl
type
label
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@ast
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@en
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@nl
prefLabel
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@ast
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@en
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@nl
P2093
P1433
P1476
Neoadjuvant and adjuvant thera ...... he randomised clinical trials.
@en
P2093
John Mandeli
Jonathan D Schwartz
Myron Schwartz
P304
P356
10.1016/S1470-2045(02)00873-2
P577
2002-10-01T00:00:00Z